If you have been diagnosed with low-risk prostate cancer, discussing management options with your doctor is typically the next step. It’s important that you give yourself time to understand what your diagnosis means, and what management option will be best for your specific cancer at this specific time.
The Oncotype DX is a genomic test, meaning that it measures the expression of certain genes in prostate cancer cells. The results of Oncotype DX are reported as a Genomic Prostate Score (GPS), which can help you and your doctor more confidently make decisions about a management plan that’s best for you.
Prostate Cancer Journey
How the test can help you
Not all prostate cancers are the same—some are aggressive and require treatment with surgery or radiation therapy. However, many are lower risk and can be managed with regular doctor visits and monitoring called active surveillance—delaying or completely avoiding treatments like surgery or radiation.
It’s important for you to understand your personal prostate cancer risk before deciding on a management plan—with this information in hand you can make a decision that is best suited to helping you live as long and healthy a life as possible. Oncotype DX GPS will help you and your health care team understand your individualized risk to better inform decisions about what happens next; active surveillance or treatment.
Hear from others who have benefitted from the test.
What the test can tell you
The Oncotype DX GPS gives you and your doctor individualized information about how aggressive the cancer is—information that’s not available from any other traditional test or tool. It:
- Analyzes the unique biology of your tumor.
- Examine gene activity inside your prostate tumor, and the role they play in your health—a science known as genomics.
- Provides a more specific and individualized assessment of whether your tumor is more or less aggressive than the biopsy results suggest.
Find out what to expect from the test and its results.
What’s needed to perform the test
The Oncotype DX GPS test uses a tissue sample from a biopsy performed within the last three years. So, if you’ve had a recent biopsy, no additional procedure is needed.
The test can predict the aggressiveness and biology of the prostate cancer without additional tests or having to remove the tumor by analyzing a very small sample of the tumor tissue.
When to have the test
If you have been recently diagnosed with low-risk prostate cancer or have yet to decide on a management option, your biopsy tissue may be used to provide additional information about the aggressiveness of your tumor, which may help you choose the right treatment plan. See if you could be eligible.
Oncotype DX GPS is the only genomic test that was designed specifically for use in men with clinically low risk cancer who are deciding between active surveillance or treatment
Discuss using the Oncotype DX GPS with your doctor to make the decision together about whether it would provide more confidence to guide important decisions about treatment. It’s essential that you have all the facts and consider your options before choosing a course of action to treat prostate cancer.
Your Oncotype DX Genomic Prostate Score Can Help You Navigate Through Your Treatment Options
Get more info on how the Oncotype DX GPS can help inform your treatment options for prostate cancer.